Asimov

Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service

Stable lentiviral (LV) cell line development service achieves unconcentrated titres >1E9 TU/mL for therapeutic transgenes Fully stable cell lines have all viral genes and transgene stably integrated, enabling biomanufacturing scalability and a more robust production process Transfection-free lentiviral manufacturing eliminates GMP plasmid cost and reduces supply chain risk for cell and gene therapy developers. 29...

Asimov launches LV Edge Packaging System to optimise lentivirus production

New off-the-shelf system reduces the cost and risk of lentiviral (LV) production for cell and gene therapy (CGT) developers. Single-plasmid transfection minimizes GMP plasmid costs and supply chain risk. System achieves high titers of >1E8 TU/mL across multiple therapeutic transgenes. 29 January 2024 -- Massachusetts, US: Asimov, the synthetic biology company advancing the design and...
Asimov, Inc. 201 Brookline Avenue Suite 1201 Boston, MA 02215

+1 (617) 849-9299